


FIGURE 1


1 2 3 4 5 6 7 8



$\beta$ -actin

II-10-1

# FIGURE 3



**FIGURE 4**




FIGURE 5A

1 2 3 4 5






FIGURE 5B

1 2 3 4 5



**FIGURE 6**



# FIGURE 7


	<b>Leader</b> -----	
RAT	ATGGGCAGTCCGGTATTTCAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG	67
MOU	-----T-----C-----A-T-----G-----	67
HUM	-----GA-----TG-----CT-----T-----G-T-----T-----G-----	55
	<b> V-like domain</b> -----	
RAT	CAGCAGTAGCGCTGAGCACAGCTCAAGTGGAAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC	134
MOU	-----GC-----	134
HUM	-----G-T-----T-----A-----C-----A-----T-----	122
RAT	AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCCTTGATTGTGACATGGCAGAAAAAG	201
MOU	-----A-----T-----	201
HUM	-----T-----AAA-C-----GC-----ATG-----G-C-C-----	189
RAT	AAAGCCGTAGGCCCAGAAAACATGGTCACTTACAGCAAAGCCCATGGGGTTGTCATTTCAGCCCACCT	268
MOU	-----GA-----C-----A-----A-C-----TG-----	268
HUM	-----T-----A-----C-T-----G-GAA-----G-G-C-----TG-----	256
RAT	ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC	335
MOU	-----TG-----A-----G-----T-----CA	335
HUM	-T-G-----A-----T-CC-----C-A--T--C-----T-TC--	323
RAT	CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA	402
MOU	-A-T-GA-----GA-C-----C-----T--CA-----A-A--	402
HUM	-----G-----A-G-T-----T-CC-----T-T-----A-A-G	390
	<b> C-like domain</b> -----	
RAT	GCTTGCCTTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAACCTATTTTGAAGACCACCTAA	469
MOU	-----C-----	469
HUM	--C-----C-CG-----TC-----A-TC-C-----	457
RAT	ACATCACGTGCTCTGCAACTGCCCCGCCAGCCCCTGCCATCTCCTGGAAGGGCACTGGGTCAGGAAT	536
MOU	-----T-----G-----T-----A-----T-----A-----	536
HUM	-T-----T-----C-----CATGG--T-----T-C-C-----	524
RAT	TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGTCACCAGCATCCTCCGGGTC	603
MOU	-----C-----T-----	603
HUM	---A-----A-T-C-TG-T-CC-----C-G-----T-----ATA--	591
RAT	AAAGACCCCAAACCTCAGGTTGGAAAGGAAGTGATCTGCCAGGTTTTATACTTGGGGAATGTGATTG	670
MOU	-----	670
HUM	-----T-G-A-----G-G-----GC-GC-C-----C-----CC-	658
	<b> Transmembrane region</b> -----	
RAT	ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCACTGCTGCTGAGCATTGTTTCTCT	737
MOU	-----T-----T-----A-----	737
HUM	---TT-----A-CCG-CA-----C-A-----T-G-AT-----A-----C--	725
	<b> Cytoplasmic region</b> -----	
RAT	GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCGAAATCAGGAGCGGGGT	804
MOU	-----A-----C-----T-----	804
HUM	-----C-C-A-----A-----C-G-----T-----G-----C-A--	792
RAT	GAGTCATCACAGGGGATGCAAAGAATGAAATAA	837
MOU	--A-----	837
HUM	---TG-----AG-T-----A-----C-----	825

1. The first step is to identify the problem. This involves understanding the current situation and what needs to be changed.

- invariant cysteine residues: •• invariant asparagine (N-linked oligosaccharides)




**FIGURE 9**




CELLS added to C57BL/6 RESPONDER SPLEEN CELLS

**FIGURE 10**




**FIGURE 11**




**NPC from Flt3 treated mice**

## FIGURE 12




# FIGURE 13




CELLS added to C3H RESPONDER SPLEEN CELLS

**FIGURE 14**




NPC cells infused into renal transplant recipients

**FIGURE 15**




**FIGURE 16**





**FIGURE 17**



**Monoclonal antibodies added to culture**

FIGURE 18A





FIGURE 18B



# Effect of anti-OX2 on spontaneous abortions



# FIGURE 20

Effect of OX2:Fc on spontaneous abortions or renal allograft rejection

CBA with C57BL/6 grafts

$p < 0.02$   
\*




Day of infusion/no. doses of OX2:Fc

FIGURE 21



3

2

1




FGL 2



OX-2

**FIGURE 22**

# **EXPRESSION OF OX-2 ON CYTOKERATIN- POSITIVE CELLS (TROPHOBLAST)**




TERM PLACENTA  
SUCCESSFUL GRAFT





TROPHOBLAST CELL  
SUSPENSION



ANTI-CD 9



CD 9<sup>-</sup> CD 9<sup>+</sup>  
TROPHOBLAST STROMA



# EXPRESSION OF OX-2 ON CYTOKERATIN- POSITIVE CELLS (TROPHOBLAST)

